Immunogenicity of the 9-valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys Vs A 3-Dose Regimen in Women

JAMA - Journal of the American Medical Association

Volumn 316, Issue 22, 2016, Pages 2411-2421

  Iversen, Ole Erik ^a   Miranda, Maria Jose ^b   Ulied, Angels ^c   Soerdal, Terje ^d   Lazarus, Erica ^e   Chokephaibulkit, Kulkanya ^f   Block, Stan L ^g   Skrivanek, Ales ^h   Azurah, Abdul Ghani Nur ⁱ   Fong, Siew Moy ^j   Dvorak, Vladimir ^k   Kim, Kyung Hyo ^l   Cestero, Ramon M ^m   Berkovitch, Matitiahu ⁿ   Ceyhan, Mehmet ^o   Ellison, Misoo C ^p   Ritter, Michael A ^p   Yuan, Shuai S ^p   Di Nubile, Mark J ^p   Saah, Alfred J ^p   Luxembourg, Alain ^p   more..

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b Instituto Chileno de Medicina Reproductiva   (Chile)

^c Centre d Atenció Primària CAO El Clot   (Spain)

^d Medicus   (Norway)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f MAHIDOL UNIVERSITY   (Thailand)

^g Kentucky Pediatric Research Institute   (United States)

^h Sro   (Czech Republic)

ⁱ UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^j Likas Women's and Children's Hospital   (Malaysia)

^k Centrum Ambulantní Gynekologie   (Czech Republic)

^l Ewha Womans University School of Medicine   (South Korea)

^m Terracina Medical Center   (United States)

ⁿ ASSAF HAROFEH MEDICAL CENTER   (Israel)

^o HACETTEPE UNIVERSITY   (Turkey)

^p MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; URTICARIA; VACCINATION; AGE; ANTIBODY SPECIFICITY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; GENOTYPE; GERIATRIC NUTRITION; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEX DIFFERENCE; TIME FACTOR; VACCINE IMMUNOGENICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODY SPECIFICITY; CHILD; COHORT STUDIES; ELDER NUTRITIONAL PHYSIOLOGICAL PHENOMENA; FEMALE; GENOTYPE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGENICITY, VACCINE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 85007461963     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.17615     Document Type: Article

References (39)

1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23.
2. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997-2008.
3. Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732-1741.
4. Alemany L, Saunier M, Alvarado-Cabrero I, et al; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1): 98-107.
5. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723.
6. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5): F123-F138.
7. Lazcano-Ponce E, StanleyM, Muñoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs a three-dose schedule at 21 months. Vaccine. 2014;32(6):725-732.
8. Donken R, Bogaards JA, van der Klis FRM, Meijer CJ, de Melker HE. An exploration of individual-and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. Hum Vaccin Immunother. 2016;12(6):1381-1393.
9. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309(17): 1793-1802.
10. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-1386.
11. Puthanakit T, Huang LM, Chiu CH, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years vs a 3-dose regimen in women aged 15-25 years. J Infect Dis. 2016;214(4):525-536.
12. Hernández-Avila M, Torres-Ibarra L, StanleyM, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30-38.
13. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43): 465-491.
14. Moreira ED Jr, Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 2016; 138(2):e20154387.
15. Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive luminex immunoassay for nine HPV types. Hum Vaccin Immunother. 2014;10(8):2168-2174.
16. WangWWB, Mehrotra DV, Chan ISF, Heyse JF. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat. 2006;16(4):429-441.
17. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196(8):1153-1162.
18. Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) vs Gardasil in 9-15-year-old girls. Pediatr Infect Dis J. 2015;34(9):992-998.
19. StanleyM, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine. 2012;30(suppl 5):F83-F87.
20. Zimmerman RK, Nowalk MP, Lin CJ, et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. JWomens Health (Larchmt). 2010;19(8):1441-1447.
21. Neuzil KM, Canh DG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: A cluster randomized noninferiority trial. JAMA. 2011;305 (14):1424-1431.
22. Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013;208(8): 1325-1334.
23. Sankaranarayanan R, Prabhu PR, Pawlita M, et al; Indian HPV Vaccine Study Group. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77.
24. European Medicines Agency. Gardasil 9: EU summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003852/WC500189111.pdf. Accessed on May 30, 2016.
25. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597-603.
26. Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: A nationwide study of 550,000 young girls. Clin Infect Dis. 2015;61(5):676-682.
27. Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE. Inconclusive evidence for non-inferior immunogenicity of two-compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. J Infect. 2015;71(1):61-73.
28. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804-2811.
29. Brotherton JM, MalloyM, Budd AC, Saville AM, Drennan K, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59-73.
30. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: A cohort study. PLoS One. 2015;10(7):e0132404.
31. Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170(5):445-452.
32. Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med. 2013;11:227.
33. Crowe E, Pandeya N, Brotherton JML, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
34. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: A population-based analysis. Br J Cancer. 2016;114 (11):1261-1264.
35. Cloessner EA, Stokley S, Yankey D, Markowitz LE. Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule. Hum Vaccin Immunother. 2016;12(6): 1375-1380.
36. Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16(5):e206-e216.
37. Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136(3):e563-e572.
38. Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015;34(6):627-634.
39. Jit M, Choi YH, Laprise JF, Boily MC, DroletM, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine. 2014;32(26):3237-3242.